Literature DB >> 26200653

Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin.

Zhineng J Yang1, Siddharth H Sheth, Chad H Smith, Amy R Schmotzer, Anita L Lippello, Ali Al-Khafaji, Kapil B Chopra, Roy E Smith.   

Abstract

Liver fibrosis in chronic liver disease (CLD) results in complex alterations in procoagulant and anticoagulant proteins. Although an elevated international normalized ratio (INR) is a prominent feature of progressive fibrosis, the utility of the INR to accurately reflect the net effect of these changes on the coagulation system is uncertain. In subjects with CLD, elevated INRs have been observed in both bleeding and thrombotic complications, suggesting limitations of the INR in characterizing the coagulation status. Unlike the INR, which is preferentially sensitive to the extrinsic pathway, the direct measurement of thrombin generation better captures the global coagulation cascade. We conducted a pilot study measuring the INR, chromogenic factor X and thrombin generation in CLD subjects and compared them with control subjects and subjects on warfarin anticoagulation. We observed a large interquartile range in thrombin generation among compensated CLD subjects across a narrow INR range, suggesting that the INR is a suboptimal surrogate measure of thrombin generation in CLD subjects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26200653      PMCID: PMC5072775          DOI: 10.1097/MBC.0000000000000365

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

1.  Interpretation of the international normalised ratio in patients with liver disease.

Authors:  Steven R Deitcher
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

Review 2.  The coagulopathy of chronic liver disease.

Authors:  Armando Tripodi; Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

3.  Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.

Authors:  Jennifer H Austin; Candace R Stearns; Anne M Winkler; Christopher A Paciullo
Journal:  Pharmacotherapy       Date:  2012-04-17       Impact factor: 4.705

4.  Use of chromogenic assay of factor X to accept or reject INR results in Warfarin treated patients.

Authors:  Michael J Sanfelippo; Wendy Zinsmaster; Doris L Scherr; Gene R Shaw
Journal:  Clin Med Res       Date:  2009-07-22

5.  Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.

Authors:  Alex Gatt; Joost J van Veen; Anita M Woolley; Steve Kitchen; Peter Cooper; Michael Makris
Journal:  Thromb Haemost       Date:  2008-08       Impact factor: 5.249

  5 in total
  1 in total

1.  Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.

Authors:  Satoshi Ueshima; Daiki Hira; Chiho Tomitsuka; Miki Nomura; Yuuma Kimura; Takuya Yamane; Yohei Tabuchi; Tomoya Ozawa; Hideki Itoh; Minoru Horie; Tomohiro Terada; Toshiya Katsura
Journal:  AAPS J       Date:  2019-06-24       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.